Loading
A German trial adding a targeted tablet to the reduced-dose chemotherapy used for older people with aggressive lymphoma, to see whether it delays relapse.
Bruton tyrosine kinase inhibitors have a clear rationale in the activated B-cell genetic subtypes of diffuse large B-cell lymphoma, which depend on chronic active B-cell receptor signalling, and a mixed record in practice: the PHOENIX trial of ibrutinib with R-CHOP improved outcomes in patients under 60 and harmed those over 60, because of toxicity rather than biology. Acalabrutinib is more selective and better tolerated.
ARCHED randomises older adults with untreated diffuse large B-cell lymphoma between R-miniCHOP alone and R-miniCHOP with acalabrutinib. The primary endpoint is investigator-assessed progression-free survival, with primary completion estimated for February 2029, and the trial is running at German sites.
It is the direct test of whether the age signal in PHOENIX was a property of ibrutinib or of the class, in the population where the answer matters most.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
A failure worth reading: the drug worked where patients could tolerate the regimen it was added to, and harmed where they could not. It is the strongest argument in lymphoma for designing first-line combinations around what an older patient can finish.
The genetic nosology that precision-medicine trials in diffuse large B-cell lymphoma now use to pick patients. It gives a mechanism, not just a label: two of the four subtypes point at a drug class that already exists.
Shares R-CHOP (lymphoma chemoimmunotherapy), B-cell receptor / BTK signalling (to NF-κB), BTK (Bruton tyrosine kinase), Older and multimorbid patients are excluded and undertreated and the tag lymphoma-evidence.
Shares R-CHOP (lymphoma chemoimmunotherapy), Prednisone, Vincristine, Rituximab and the tag lymphoma-evidence.
Shares Cell of origin (GCB vs ABC), R-CHOP (lymphoma chemoimmunotherapy), CD20, Prednisone and the tag lymphoma-evidence.
Shares R-CHOP (lymphoma chemoimmunotherapy), B-cell receptor / BTK signalling (to NF-κB), BTK (Bruton tyrosine kinase), Older and multimorbid patients are excluded and undertreated and the tag lymphoma-evidence.
Shares Cell of origin (GCB vs ABC), R-CHOP (lymphoma chemoimmunotherapy), CD20, Prednisone and the tag lymphoma-evidence.
Shares R-CHOP (lymphoma chemoimmunotherapy), Prednisone, Vincristine, Rituximab and the tag lymphoma-evidence.
Shares R-CHOP (lymphoma chemoimmunotherapy), Prednisone, Vincristine, Rituximab and the tag lymphoma-evidence.
Shares R-CHOP (lymphoma chemoimmunotherapy), Prednisone, Vincristine, Rituximab and the tag lymphoma-evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/